{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:52:20Z","timestamp":1768510340692,"version":"3.49.0"},"posted":{"date-parts":[[2024,3,27]]},"group-title":"Pharmacology and Toxicology","reference-count":141,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Glucocerebrosidase (GCase) is implicated in both a rare, monogenic disorder (Gaucher disease, GD) and a common, multifactorial condition (Parkinson\u2019s disease); hence, it is an urgent therapeutic target. To identify correctors of severe protein misfolding and trafficking obstruction manifested by the pathogenic L444P-variant of GCase, we developed a suite of quantitative, high-throughput, cell-based assays. First, we labeled GCase with a small pro-luminescent HiBiT peptide reporter tag, enabling quantitation of protein stabilization in cells while faithfully maintaining target biology. TALEN-based gene editing allowed for stable integration of a single HiBiT-\n                  <jats:italic>GBA1<\/jats:italic>\n                  transgene into an intragenic safe-harbor locus in\n                  <jats:italic>GBA1<\/jats:italic>\n                  -knockout H4 (neuroglioma) cells. This GD cell model was amenable to lead discovery via titration-based quantitative high-throughput screening and lead optimization via structure-activity relationships. A primary screen of 10,779 compounds from the NCATS bioactive collections identified 140 stabilizers of HiBiT-GCase-L444P, including both pharmacological chaperones (ambroxol and non-inhibitory chaperone NCGC326) and proteostasis regulators (panobinostat, trans-ISRIB, and pladienolide B). Two complementary high-content imaging-based assays were deployed to triage hits: the fluorescence-quenched substrate LysoFix-GBA captured functional lysosomal GCase activity, while an immunofluorescence assay featuring antibody hGCase-1\/23 provided direct visualization of GCase lysosomal translocation. NCGC326 was active in both secondary assays and completely reversed pathological glucosylsphingosine accumulation. Finally, we tested the concept of combination therapy, by demonstrating synergistic actions of NCGC326 with proteostasis regulators in enhancing GCase-L444P levels. Looking forward, these physiologically-relevant assays can facilitate the identification, pharmacological validation, and medicinal chemistry optimization of new chemical matter targeting GCase, ultimately leading to a viable therapeutic for two protein-misfolding diseases.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Significance Statement<\/jats:title>\n                  <jats:p>\n                    Gaucher disease, the inherited deficiency of glucocerebrosidase, is caused by biallelic, loss-of-function mutations in the gene\n                    <jats:italic>GBA1,<\/jats:italic>\n                    which is also the most frequent genetic risk factor for Parkinson\u2019s disease. While the development of small-molecule stabilizers of glucocerebrosidase is being considered for both disorders, discovery and optimization of lead compounds is limited by the lack of robust cell-based assays amenable to high-throughput screening format. We developed a comprehensive assay pipeline for preclinical discovery of glucocerebrosidase modulators and began by screening libraries enriched with bioactive compounds with known mechanisms of action. The screen identified chemical matter with established relevance to glucocerebrosidase, provided an atlas of potential new molecular targets regulating the\n                    <jats:italic>GBA1<\/jats:italic>\n                    pathway, and produced a set of promising potential therapeutics.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.03.22.586364","type":"posted-content","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:45:48Z","timestamp":1711550748000},"source":"Crossref","is-referenced-by-count":3,"title":["Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded \u03b2-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson\u2019s disease"],"prefix":"10.64898","author":[{"given":"Darian","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan M.","family":"Glasstetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany T.","family":"Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gehrlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vocadlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Marugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-7338","authenticated-orcid":false,"given":"Mark J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7309","authenticated-orcid":false,"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024032908500520000_2024.03.22.586364v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901281"},{"issue":"6","key":"2024032908500520000_2024.03.22.586364v1.2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","year":"2013","journal-title":"JAMA Neurol"},{"key":"2024032908500520000_2024.03.22.586364v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-014-0294-x"},{"key":"2024032908500520000_2024.03.22.586364v1.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220464110"},{"issue":"7","key":"2024032908500520000_2024.03.22.586364v1.5","first-page":"e1036","article-title":"Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease","volume":"96","year":"2021","journal-title":"Neurology"},{"key":"2024032908500520000_2024.03.22.586364v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28932"},{"key":"2024032908500520000_2024.03.22.586364v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01150-6"},{"key":"2024032908500520000_2024.03.22.586364v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37632-4"},{"key":"2024032908500520000_2024.03.22.586364v1.9","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.112171"},{"key":"2024032908500520000_2024.03.22.586364v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.10.006"},{"key":"2024032908500520000_2024.03.22.586364v1.11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-51"},{"issue":"8","key":"2024032908500520000_2024.03.22.586364v1.12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"2024032908500520000_2024.03.22.586364v1.13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial","volume":"77","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024032908500520000_2024.03.22.586364v1.14","doi-asserted-by":"crossref","unstructured":"Burbulla LF , Jeon S , Zheng J , Song P , Silverman RB , Krainc D . A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease. Sci Transl Med. 2019;11(514).","DOI":"10.1126\/scitranslmed.aau6870"},{"key":"2024032908500520000_2024.03.22.586364v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.06.001"},{"key":"2024032908500520000_2024.03.22.586364v1.16","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.013474"},{"key":"2024032908500520000_2024.03.22.586364v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2005.05.008"},{"key":"2024032908500520000_2024.03.22.586364v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22124"},{"key":"2024032908500520000_2024.03.22.586364v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.10.012"},{"key":"2024032908500520000_2024.03.22.586364v1.20","doi-asserted-by":"publisher","DOI":"10.1021\/cb600187q"},{"key":"2024032908500520000_2024.03.22.586364v1.21","doi-asserted-by":"publisher","DOI":"10.1021\/cb100321m"},{"key":"2024032908500520000_2024.03.22.586364v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.04.018"},{"key":"2024032908500520000_2024.03.22.586364v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2546"},{"key":"2024032908500520000_2024.03.22.586364v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi240"},{"key":"2024032908500520000_2024.03.22.586364v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.embor873"},{"key":"2024032908500520000_2024.03.22.586364v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70190-4"},{"key":"2024032908500520000_2024.03.22.586364v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.06.037"},{"key":"2024032908500520000_2024.03.22.586364v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.368"},{"key":"2024032908500520000_2024.03.22.586364v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2012.11.014"},{"key":"2024032908500520000_2024.03.22.586364v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0584-z"},{"key":"2024032908500520000_2024.03.22.586364v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.763"},{"key":"2024032908500520000_2024.03.22.586364v1.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.052308.114844"},{"key":"2024032908500520000_2024.03.22.586364v1.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192582899"},{"key":"2024032908500520000_2024.03.22.586364v1.34","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b13003"},{"issue":"10","key":"2024032908500520000_2024.03.22.586364v1.35","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1002\/anie.202013890","article-title":"Novel \u03b2-Glucocerebrosidase Activators That Bind to a New Pocket at a Dimer Interface and Induce Dimerization","volume":"60","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"2024032908500520000_2024.03.22.586364v1.36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbrc.2015.01.024","article-title":"Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C","volume":"457","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2024032908500520000_2024.03.22.586364v1.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605928103"},{"key":"2024032908500520000_2024.03.22.586364v1.38","doi-asserted-by":"publisher","DOI":"10.1021\/jm060677i"},{"key":"2024032908500520000_2024.03.22.586364v1.39","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.200800304"},{"key":"2024032908500520000_2024.03.22.586364v1.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705637104"},{"key":"2024032908500520000_2024.03.22.586364v1.41","doi-asserted-by":"publisher","DOI":"10.1021\/jm1008902"},{"key":"2024032908500520000_2024.03.22.586364v1.42","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.569162"},{"key":"2024032908500520000_2024.03.22.586364v1.43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.012393"},{"key":"2024032908500520000_2024.03.22.586364v1.44","doi-asserted-by":"crossref","unstructured":"Migdalska-Richards A , Ko WKD , Li Q , Bezard E , Schapira AHV . Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017;71(7).","DOI":"10.1002\/syn.21967"},{"issue":"3","key":"2024032908500520000_2024.03.22.586364v1.45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2024032908500520000_2024.03.22.586364v1.46","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106132"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","year":"2019","journal-title":"BMC Neurol"},{"key":"2024032908500520000_2024.03.22.586364v1.48","doi-asserted-by":"crossref","first-page":"1163184","DOI":"10.3389\/fnagi.2023.1163184","article-title":"The ANeED study - ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial","volume":"15","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"2024032908500520000_2024.03.22.586364v1.49","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/mds.28815","article-title":"Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity","volume":"36","year":"2021","journal-title":"Mov Disord"},{"key":"2024032908500520000_2024.03.22.586364v1.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604348103"},{"key":"2024032908500520000_2024.03.22.586364v1.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029861"},{"key":"2024032908500520000_2024.03.22.586364v1.52","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0636-16.2016"},{"key":"2024032908500520000_2024.03.22.586364v1.53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008659"},{"key":"2024032908500520000_2024.03.22.586364v1.54","doi-asserted-by":"publisher","DOI":"10.1021\/jm300063b"},{"key":"2024032908500520000_2024.03.22.586364v1.55","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0628-16.2016"},{"key":"2024032908500520000_2024.03.22.586364v1.56","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00549"},{"issue":"4","key":"2024032908500520000_2024.03.22.586364v1.57","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1021\/acsptsci.1c00110","article-title":"Genome-Edited Coincidence and PMP22-HiBiT Fusion Reporter Cell Lines Enable an Artifact-Suppressive Quantitative High-Throughput Screening Strategy for PMP22 Gene-Dosage Disorder Drug Discovery","volume":"4","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"2024032908500520000_2024.03.22.586364v1.58","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1021\/acschembio.0c00343","article-title":"High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle","volume":"15","year":"2020","journal-title":"ACS Chem Biol"},{"issue":"8","key":"2024032908500520000_2024.03.22.586364v1.59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/adt.2021.059","article-title":"A Genome-Edited ER\u03b1-HiBiT Fusion Reporter Cell Line for the Identification of ER\u03b1 Modulators Via High-Throughput Screening and CETSA","volume":"19","year":"2021","journal-title":"Assay Drug Dev Technol"},{"key":"2024032908500520000_2024.03.22.586364v1.60","doi-asserted-by":"crossref","unstructured":"Naito Y , Sakamoto S , Kojima T , Homma M , Tanaka M , Matsui H. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells. SLAS Discov. 2023.","DOI":"10.1016\/j.slasd.2023.06.002"},{"key":"2024032908500520000_2024.03.22.586364v1.61","doi-asserted-by":"crossref","unstructured":"Zhu S , Deen MC , Zhu Y , Gilormini PA , Chen X , Davis OB , et al. A Fixable Fluorescence-Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells. Angew Chem Int Ed Engl. 2023:e202309306.","DOI":"10.1002\/anie.202309306"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JPD-230295","article-title":"Characterization of Novel Human \u03b2-glucocerebrosidase Antibodies for Parkinson\u2019s Disease Research","volume":"14","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2024032908500520000_2024.03.22.586364v1.63","doi-asserted-by":"crossref","unstructured":"Fredriksen K , Aivazidis S , Sharma K , Burbidge KJ , Pitcairn C , Zunke F , et al. Pathological \u03b1-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of \u03b1-syn in vivo. Proc Natl Acad Sci U S A. 2021;118(50).","DOI":"10.1073\/pnas.2108489118"},{"key":"2024032908500520000_2024.03.22.586364v1.64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001862"},{"key":"2024032908500520000_2024.03.22.586364v1.65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00914-16"},{"key":"2024032908500520000_2024.03.22.586364v1.66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116032"},{"issue":"2","key":"2024032908500520000_2024.03.22.586364v1.67","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","article-title":"CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons","volume":"104","year":"2019","journal-title":"Neuron"},{"key":"2024032908500520000_2024.03.22.586364v1.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00320-3"},{"key":"2024032908500520000_2024.03.22.586364v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2012.10.007"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1432-1033.1987.tb11008.x","article-title":"Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts","volume":"164","year":"1987","journal-title":"Eur J Biochem"},{"key":"2024032908500520000_2024.03.22.586364v1.71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424288112"},{"key":"2024032908500520000_2024.03.22.586364v1.72","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.274332"},{"key":"2024032908500520000_2024.03.22.586364v1.73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119181109"},{"key":"2024032908500520000_2024.03.22.586364v1.74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1221046110"},{"key":"2024032908500520000_2024.03.22.586364v1.75","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2017.1302045"},{"key":"2024032908500520000_2024.03.22.586364v1.76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00498"},{"key":"2024032908500520000_2024.03.22.586364v1.77","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.26"},{"issue":"9","key":"2024032908500520000_2024.03.22.586364v1.78","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1111\/bcp.14772","article-title":"A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator","volume":"87","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2024032908500520000_2024.03.22.586364v1.79","doi-asserted-by":"crossref","unstructured":"den Heijer JM , Kruithof AC , Moerland M , Walker M , Dudgeon L , Justman C , et al. A Phase 1B Trial in GBA1-Associated Parkinson\u2019s Disease of BIA-28-6156, a Glucocerebrosidase Activator. Mov Disord. 2023.","DOI":"10.1002\/mds.29346"},{"key":"2024032908500520000_2024.03.22.586364v1.80","unstructured":"Bray MA , Carpenter A , Imaging Platform BIoMIT, Harvard. Advanced Assay Development Guidelines for Image-Based High Content Screening and Analysis. In: Markossian S , Grossman A , Brimacombe K , Arkin M , Auld D , Austin C , et al., editors. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004."},{"issue":"4","key":"2024032908500520000_2024.03.22.586364v1.81","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.stemcr.2017.08.019","article-title":"Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening","volume":"9","year":"2017","journal-title":"Stem Cell Reports"},{"key":"2024032908500520000_2024.03.22.586364v1.82","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy117"},{"key":"2024032908500520000_2024.03.22.586364v1.83","doi-asserted-by":"publisher","DOI":"10.1086\/302925"},{"key":"2024032908500520000_2024.03.22.586364v1.84","unstructured":"Consortium TP , coordination O, Elsasser S , Elia LP , Morimoto RI , Powers ET , et al. A Comprehensive Enumeration of the Human Proteostasis Network. 1. Components of Translation, Protein Folding, and Organelle-Specific Systems. bioRxiv. 2022:2022.08.30.505920."},{"key":"2024032908500520000_2024.03.22.586364v1.85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060614-033955"},{"key":"2024032908500520000_2024.03.22.586364v1.86","doi-asserted-by":"publisher","DOI":"10.2174\/1568026611212220014"},{"key":"2024032908500520000_2024.03.22.586364v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.018"},{"key":"2024032908500520000_2024.03.22.586364v1.88","doi-asserted-by":"crossref","unstructured":"Schulze MED , Scholz D , Jnoff E , Hall A , Melin J , Sands ZA , et al. Identification of \u00df-Glucocerebrosidase Activators for Glucosylceramide hydrolysis. ChemMedChem. 2024:e202300548.","DOI":"10.1002\/cmdc.202300548"},{"key":"2024032908500520000_2024.03.22.586364v1.89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ebiom.2016.10.010","article-title":"Progranulin Recruits HSP70 to \u03b2-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease","volume":"13","year":"2016","journal-title":"EBioMedicine"},{"key":"2024032908500520000_2024.03.22.586364v1.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.04.024"},{"key":"2024032908500520000_2024.03.22.586364v1.91","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz350"},{"key":"2024032908500520000_2024.03.22.586364v1.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.07.085"},{"key":"2024032908500520000_2024.03.22.586364v1.93","doi-asserted-by":"crossref","first-page":"129130","DOI":"10.1016\/j.bmcl.2023.129130","article-title":"Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones","volume":"81","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"2024032908500520000_2024.03.22.586364v1.94","doi-asserted-by":"publisher","DOI":"10.2174\/138620708786734244"},{"issue":"18","key":"2024032908500520000_2024.03.22.586364v1.95","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1021\/acs.jmedchem.6b00930","article-title":"Design and Synthesis of Potent Quinazolines as Selective \u03b2-Glucocerebrosidase Modulators","volume":"59","year":"2016","journal-title":"J Med Chem"},{"issue":"4","key":"2024032908500520000_2024.03.22.586364v1.96","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/2472555220985049","article-title":"High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics","volume":"26","year":"2021","journal-title":"SLAS Discov"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.97","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-020-65832-1","article-title":"A Simple and Scalable Strategy for Analysis of Endogenous Protein Dynamics","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"2024032908500520000_2024.03.22.586364v1.98","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E15-07-0512"},{"key":"2024032908500520000_2024.03.22.586364v1.99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","article-title":"Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism","volume":"84","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"2024032908500520000_2024.03.22.586364v1.100","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.275"},{"key":"2024032908500520000_2024.03.22.586364v1.101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014890108"},{"key":"2024032908500520000_2024.03.22.586364v1.102","doi-asserted-by":"publisher","DOI":"10.1038\/35099568"},{"key":"2024032908500520000_2024.03.22.586364v1.103","doi-asserted-by":"publisher","DOI":"10.1126\/science.1128294"},{"key":"2024032908500520000_2024.03.22.586364v1.104","first-page":"303294","article-title":"Targeting histone deacetylases: a novel approach in Parkinson\u2019s disease","volume":"2015","year":"2015","journal-title":"Parkinsons Dis"},{"issue":"6","key":"2024032908500520000_2024.03.22.586364v1.105","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.stemcr.2017.10.029","article-title":"Altered Differentiation Potential of Gaucher\u2019s Disease iPSC Neuronal Progenitors due to Wnt\/\u03b2-Catenin Downregulation","volume":"9","year":"2017","journal-title":"Stem Cell Reports"},{"issue":"5","key":"2024032908500520000_2024.03.22.586364v1.106","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/hmg\/ddx442","article-title":"Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition","volume":"27","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.107","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-022-00554-8","article-title":"Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson\u2019s disease","volume":"17","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2024032908500520000_2024.03.22.586364v1.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.03.011"},{"key":"2024032908500520000_2024.03.22.586364v1.109","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-021-00450-1"},{"key":"2024032908500520000_2024.03.22.586364v1.110","doi-asserted-by":"crossref","unstructured":"Kim Guisbert KS , Mossiah I , Guisbert E . Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology. Int J Mol Sci. 2020;21(24).","DOI":"10.3390\/ijms21249641"},{"key":"2024032908500520000_2024.03.22.586364v1.111","doi-asserted-by":"crossref","unstructured":"Costa-Mattioli M , Walter P . The integrated stress response: From mechanism to disease. Science. 2020;368(6489).","DOI":"10.1126\/science.aat5314"},{"key":"2024032908500520000_2024.03.22.586364v1.112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815767116"},{"key":"2024032908500520000_2024.03.22.586364v1.113","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.49"},{"key":"2024032908500520000_2024.03.22.586364v1.114","doi-asserted-by":"crossref","unstructured":"Oliveira MM , Lourenco MV , Longo F , Kasica NP , Yang W , Ureta G , et al. Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer\u2019s disease. Sci Signal. 2021;14(668).","DOI":"10.1126\/scisignal.abc5429"},{"key":"2024032908500520000_2024.03.22.586364v1.115","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024032908500520000_2024.03.22.586364v1.116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111"},{"key":"2024032908500520000_2024.03.22.586364v1.117","doi-asserted-by":"crossref","unstructured":"Lin GL , Wilson KM , Ceribelli M , Stanton BZ , Woo PJ , Kreimer S , et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11(519).","DOI":"10.1126\/scitranslmed.aaw0064"},{"key":"2024032908500520000_2024.03.22.586364v1.118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352971"},{"issue":"1-2","key":"2024032908500520000_2024.03.22.586364v1.119","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","article-title":"Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials","volume":"122","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2024032908500520000_2024.03.22.586364v1.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2003.08.016"},{"issue":"11","key":"2024032908500520000_2024.03.22.586364v1.121","doi-asserted-by":"crossref","first-page":"e0277058","DOI":"10.1371\/journal.pone.0277058","article-title":"Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells","volume":"17","year":"2022","journal-title":"PLoS One"},{"key":"2024032908500520000_2024.03.22.586364v1.122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1982.tb07950.x"},{"key":"2024032908500520000_2024.03.22.586364v1.123","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bcmd.2016.10.025","article-title":"UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher disease","volume":"68","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.124","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"2024032908500520000_2024.03.22.586364v1.125","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01126-2"},{"key":"2024032908500520000_2024.03.22.586364v1.126","doi-asserted-by":"crossref","unstructured":"Cerbini T , Luo Y , Rao MS , Zou J . Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor. J Vis Exp. 2015(96).","DOI":"10.3791\/52504"},{"key":"2024032908500520000_2024.03.22.586364v1.127","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E17-03-0209"},{"issue":"1","key":"2024032908500520000_2024.03.22.586364v1.128","doi-asserted-by":"crossref","first-page":"100340","DOI":"10.1016\/j.xpro.2021.100340","article-title":"Analysis of lysosomal hydrolase trafficking and activity in human iPSC-derived neuronal models","volume":"2","year":"2021","journal-title":"STAR Protoc"},{"key":"2024032908500520000_2024.03.22.586364v1.129","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6741-1_3"},{"key":"2024032908500520000_2024.03.22.586364v1.130","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-322-0_22"},{"key":"2024032908500520000_2024.03.22.586364v1.131","doi-asserted-by":"publisher","DOI":"10.1139\/o59-099"},{"key":"2024032908500520000_2024.03.22.586364v1.132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-0716-2213-1_13","article-title":"A Quantitative High-Throughput Screening Data Analysis Pipeline for Activity Profiling","volume":"2474","year":"2022","journal-title":"Methods Mol Biol"},{"key":"2024032908500520000_2024.03.22.586364v1.133","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1075"},{"key":"2024032908500520000_2024.03.22.586364v1.134","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad976"},{"issue":"D1","key":"2024032908500520000_2024.03.22.586364v1.135","doi-asserted-by":"crossref","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024","volume":"52","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2024032908500520000_2024.03.22.586364v1.136","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2350"},{"key":"2024032908500520000_2024.03.22.586364v1.137","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac956"},{"key":"2024032908500520000_2024.03.22.586364v1.138","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1003"},{"issue":"D1","key":"2024032908500520000_2024.03.22.586364v1.139","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2024032908500520000_2024.03.22.586364v1.140","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa216"},{"issue":"2","key":"2024032908500520000_2024.03.22.586364v1.141","first-page":"331","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","year":"1995","journal-title":"Pharmacol Rev"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.03.22.586364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:09:44Z","timestamp":1768457384000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.03.22.586364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":141,"URL":"https:\/\/doi.org\/10.1101\/2024.03.22.586364","relation":{},"subject":[],"published":{"date-parts":[[2024,3,27]]},"subtype":"preprint"}}